AK MPJE cheat sheet

Federal Controlled Substances Act scheduling is set by 21 CFR Part 1308; Alaska adopts the federal schedules by reference in state statute.

DEA registration must be renewed every 3 years for pharmacies and practitioners; Alaska pharmacy licensure renews on a separate cycle set by the Board of Pharmacy.

Federal legend drug labeling requires the Rx symbol or statement 'Caution: Federal law prohibits dispensing without prescription.'

Alaska requires an in-state licensed pharmacist to be the pharmacist-in-charge (PIC) responsible for compliance at each licensed pharmacy.

A prescription drug order may be transferred between pharmacies under federal rules only when both pharmacies share a real-time electronic database or the transfer is documented per state rule.

Alaska law permits pharmacists to dispense up to a 90-day supply of a maintenance medication in defined emergency situations with prescriber notification requirements.

FDA-approved drug products may be substituted for brand-name prescriptions unless the prescriber writes 'dispense as written' or the patient objects.

Recordkeeping for prescription drugs generally requires retention of records for at least 2 years under federal rules; Alaska imposes its own longer retention for certain records.

Alaska pharmacist licensure requires graduation from an ACPE-accredited program, passage of NAPLEX and MPJE, and completion of required internship hours.

Pharmacist licenses in Alaska renew biennially; continuing education is required per Board rule (30 hours per renewal cycle, including specific mandated topics).

Pharmacy technician registration in Alaska requires Board registration; technicians work under direct pharmacist supervision and cannot perform final verification.

Pharmacy interns must register with the Board and practice under a supervising pharmacist; intern registration is time-limited and tied to the academic program.

License renewal applications must disclose any criminal convictions, disciplinary actions, or impairments since the last renewal; failure to disclose is grounds for discipline.

A pharmacist licensed in another state may obtain an Alaska license by reciprocity/licensure by credentials if the original license was obtained by examination and is in good standing.

Lapsed licenses may be reinstated within a defined grace period upon payment of fees and completion of CE; practicing on a lapsed license is unlicensed practice.

Change of address or name must be reported to the Board within a set timeframe; failure to update records can affect renewal validity.

Schedule II prescriptions require a written or electronic prescription; federal law limits refills to zero and requires a new prescription for each fill.

Alaska permits emergency oral Schedule II prescriptions with a written follow-up prescription delivered to the pharmacy within 7 days.

PDMP (Prescription Drug Monitoring Program) queries are required for pharmacists before dispensing certain controlled substances under Alaska rules; reporting of dispensed CS is mandatory.

Schedule III–V prescriptions may be refilled up to 5 times within 6 months of the issue date unless the prescriber specifies otherwise.

DEA Form 222 (or CSOS) is required for ordering Schedule II substances; Schedule III–V ordering uses invoices and does not require Form 222.

A biennial inventory of controlled substances is required; newly scheduled drugs must be inventoried on the effective date of scheduling.

Theft or significant loss of controlled substances must be reported to DEA in writing within one business day of discovery, and to the Alaska Board.

Electronic prescriptions for controlled substances require DEA-compliant EPCS systems with identity proofing and two-factor authentication.

A prescription must contain the patient name, drug name/strength/quantity, directions, prescriber name and DEA number (for CS), and date of issue.

Alaska requires the pharmacy label to include the pharmacy name and address, prescription number, date, patient name, drug name and strength, directions, and prescriber name.

Patient counseling must be offered by the pharmacist on new prescriptions; counseling may be declined by the patient and the refusal documented.

Prescriptions may be refilled only if authorized; the pharmacist must verify refill authorization and record the refill date and quantity.

Generic substitution requires the pharmacist to inform the patient of the substitution and record the substitution on the prescription record.

A prescription is valid for one year from the date of issue unless state law or the prescriber specifies a shorter period.

Pharmacists must verify prescription authenticity, including prescriber DEA registration for controlled substances, before dispensing.

Dispensing errors and adverse events must be documented and reported per pharmacy policy and Board requirements.

Pharmacies must maintain a secure area for controlled substances with limited access; Schedule II drugs must be stored in a locked cabinet or dispersed with audit trail.

Refrigerators used for drug storage must have a calibrated thermometer and temperature logs; drugs requiring cold chain must be monitored continuously.

The pharmacy must have a sink with hot and cold running water, adequate lighting, and a designated prescription compounding area.

Expired drugs must be segregated and removed from active inventory; outdated stock cannot be dispensed.

Controlled substance records, inventories, and dispensing logs must be kept on-site and available for inspection by DEA and Board inspectors.

Alaska requires pharmacies to maintain a written policy and procedure manual covering dispensing, security, and emergency operations.

Automated dispensing systems must have audit trails and be subject to pharmacist verification; override access must be documented.

Security requirements include alarm systems, restricted keys, and access logs for the controlled substance storage area.

Grounds for discipline include fraud, deceit, unprofessional conduct, impairment, and violation of pharmacy law or Board rules.

The Board may impose reprimand, probation, suspension, revocation, or civil penalties; disciplinary actions are reported to national databases.

Mandatory reporting: pharmacists must report suspected impairment or diversion by colleagues to the Board or a designated program.

Alaska has a pharmacist recovery/assistance program; participation may be a condition of probation or reinstatement.

Unprofessional conduct includes dispensing without a valid prescription, falsifying records, and practicing outside scope.

Due process: licensees are entitled to notice and a hearing before the Board; appeals go to the superior court.

Confidentiality of patient records is required; unauthorized disclosure is a violation and grounds for discipline.

Continuing education noncompliance and failure to report changes can trigger disciplinary action or license suspension.

Sterile compounding must follow USP <797> standards for environmental monitoring, personnel training, and beyond-use dating.

Non-sterile compounding follows USP <795>; compounded preparations require a master formulation record and a compounding record.

Institutional pharmacies must have a pharmacy and therapeutics committee and a formulary system approved by medical staff.

Unit-dose and floor-stock distribution systems require pharmacist review and control; automated cabinets must have override audit trails.

Compounding of copies of commercially available products is generally not permitted unless a documented clinical need exists.

Hazardous drug handling follows USP <800> for containment, PPE, and environmental monitoring.

Institutional controlled substance records must be reconciled at shift change and discrepancies reported to the pharmacy.

Drug distribution to long-term care facilities requires a consultant pharmacist for medication regimen review and quality assurance.